- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01927562
Initial Clinical Evaluation of an Endoscopic Therapy for Type 2 Diabetes
February 12, 2024 updated by: Fractyl Health Inc.
Evaluation of the Fractyl Duodenal Remodeling System for the Treatment of Type 2 Diabetes
The purpose of this study is to assess the safety and feasibility of the Fractyl Duodenal Remodeling System for the treatment of patients with poorly controlled Type 2 Diabetes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The purpose of this protocol is to evaluate the initial safety profile of the Fractyl System and its effect on participants with Type 2 Diabetes.
This will be determined through the monitoring of adverse events and outcome measures including Mixed Meal Tolerance Test (MMTT).
Study Type
Interventional
Enrollment (Actual)
57
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Santiago, Chile
- INDISA
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
28 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants Age > 28 years and ≤ 75 years
- Male or Female
- Participants with Type 2 Diabetes who are treated for ≤ 10 years and are on stable oral diabetic medications for a minimum of 3 months
- Participants with an HbA1c > 7.5 and ≤ 10.0%
- Participants with a BMI > 24 and < 40
- Participants willing to comply with study requirements and able to understand and comply with informed consent
- Participants who have signed an informed consent form
Exclusion Criteria:
- Participants diagnosed with Type I Diabetes or with a history of ketoacidosis
- Participants using insulin for more than 12 months
- Participants with probable insulin production failure (defined as fasting C Peptide serum <1ng/mL)
- Participants that have known autoimmune disease as evidenced by a positive anti glutamic acid decarboxylase (GAD) blood test
- Participants requiring prescription anticoagulation therapy and/or dual anti-platelet therapy including aspirin who cannot discontinue their medication for 14 days before and 14 days after the procedure
- Participants with iron deficiency anemia - either currently or in their history
- Participants with current symptomatic hypocalcemia or vitamin D deficiency (routine calcium and/or vitamin D supplementation would not be excluded)
- Participants with or a history of abnormalities of the GI tract preventing endoscopic access to the duodenum,
- Participants with symptomatic gallstones or kidney stones at the time of screening
- Participants with a history of pancreatitis
- Participants with an active systemic infection
- Participants with or a history of coagulopathy, upper gastro-intestinal bleeding c conditions such as ulcers, gastric varices, strictures, congenital or acquired intestinal telangiectasia
- Participants with celiac disease
- Participants with active malignancy. Those who have had remedial treatment and/or are cancer free for 5 years can be enrolled
- Participants with known active hepatitis or active liver disease
- Participants emotionally unstable or who exhibit psychological characteristics which, in the opinion of the Investigator, make the participant a poor candidate for clinical trial participation
- Participants with previous GI surgery that could affect the ability to treat the duodenum such as participants who have had a Bilroth 2, Roux-en-Y gastric bypass, or other similar procedures or conditions
- Participants unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during treatment through 2 weeks post procedure phase
- Participants receiving weight loss medications such as Meridia, Xenical, or over the counter weight loss medications
- Participant with a known diagnosis or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder
- Participants with active and uncontrolled gastroesophageal reflux disease (GERD) defined as grade II esophagitis or greater
- Participants with active illicit substance abuse or alcoholism
- Participants participating in another ongoing investigational clinical trial
- Participants taking corticosteroids or drugs known to affect GI motility (i.e. Reglan)
- Participants who are not potential candidates for duodenal exclusion surgery or general anesthesia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Duodenal Treatment
The Duodenal Remodeling procedure utilizes both a trans-oral over the wire and endoscopic approach to minimally invasively ablating and remodeling the duodenum.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changed in Mixed Meal Tolerance From Baseline to 3 Months
Time Frame: 3 months
|
Improvement in fasting plasma glucose based on Mixed Meal Tolerance Test between baseline and 3 months
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Leonard R Gomez, MD, Centro Clinico De La Obesidad
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 13, 2013
Primary Completion (Actual)
April 7, 2017
Study Completion (Actual)
March 16, 2018
Study Registration Dates
First Submitted
August 20, 2013
First Submitted That Met QC Criteria
August 21, 2013
First Posted (Estimated)
August 22, 2013
Study Record Updates
Last Update Posted (Estimated)
February 14, 2024
Last Update Submitted That Met QC Criteria
February 12, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-10000
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type II Diabetes
-
Microbio Co LtdCompleted
-
pico-tesla Magnetic Therapies, LLCCompletedType II Diabetes MellitusUnited States
-
HealthInsightCenter for Technology and Aging; VoxivaUnknownType II Diabetes MellitusUnited States
-
KeyBioscience AGEli Lilly and Company; Profil Institut für Stoffwechselforschung GmbH; Nordic...TerminatedType II Diabetes MellitusGermany
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Khoo Teck Puat HospitalCompletedType II Diabetes in Subjects BMI 27 to 32Singapore
-
University of PretoriaNestlè Nutrition Institute Africa; South African Sugar AssociationCompletedDiabetes Mellitus, Type II [Non-insulin Dependent Type] [NIDDM Type] UncontrolledSouth Africa
-
University of PrimorskaUniversity of Ljubljana School of Medicine, SloveniaCompletedDiabetes Mellitus Type II,Slovenia
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
Clinical Trials on Fractyl Duodenal Remodeling System
-
Medical College of WisconsinTerminatedObesity | Type-2 Diabetes MellitusUnited States
-
Samsung Medical CenterCompletedGastric Outlet Obstruction Due to Gastric AdenocarcinomaKorea, Republic of
-
Chinese University of Hong KongCompletedGastric Outlet ObstructionHong Kong
-
Evasc Medical Systems Corp.Withdrawn
-
Meshalkin Research Institute of Pathology of CirculationCompletedStenosis, Internal Carotid ArteryRussian Federation
-
Cleveland Clinic LondonRecruitingObesity | Diabetes Mellitus, Type 2United Kingdom
-
Ruhr University of BochumCompletedObesity | Type 2 Diabetes MellitusGermany
-
Ryazan State Medical UniversityActive, not recruitingVascular Diseases | Varicose Veins of Lower Limb | Leg Edema | VarixRussian Federation
-
Sandwell & West Birmingham Hospitals NHS TrustAssociation of British Clinical DiabetologistsUnknownObesity | Type 2 Diabetes | DiabesityUnited Kingdom
-
St. James's Hospital, IrelandCompletedNutrition Disorders | Esophageal Cancer | Surgery | Delayed Gastric Emptying | Appetite Disorders | Dumping SyndromeIreland